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ABSTRACT
OBJECTIVE: To estimate the budget impact from the incorporation of 
positron emission tomography (PET) in mediastinal and distant staging of 
non-small cell lung cancer.
METHODS: The estimates were calculated by the epidemiological method 
for years 2014 to 2018. Nation-wide data were used about the incidence; 
data on distribution of the disease´s prevalence and on the technologies 
accuracy were from the literature; data regarding involved costs were taken 
IURP D PLFURFRVWLQJ VWXG\ DQG IURP %UD]LOLDQ 8QL¿HG +HDOWK 6\VWHP
686GDWDEDVH7ZRVWUDWHJLHVIRUXVLQJ3(7ZHUHDQDO\]HGWKHRIIHUWR
all newly-diagnosed patients, and the restricted offer to the ones who had 
negative results in previous computed tomography (CT) exams. Univariate 
and extreme scenarios sensitivity analyses were conducted to evaluate the 
LQÀXHQFHIURPVRXUFHVRIXQFHUWDLQWLHVLQWKHSDUDPHWHUVXVHG
RESULTS:7KHLQFRUSRUDWLRQRI3(7&7LQ686ZRXOGLPSO\WKHQHHGIRU
DGGLWLRQDOUHVRXUFHVRI%5/86'PLOOLRQIRUWKHUHVWULFWHGRIIHU
DQG%5/86'PLOOLRQIRUWKHLQFOXVLYHRIIHULQ¿YH\HDUV
ZLWKDGLIIHUHQFHRI%5/86'PLOOLRQEHWZHHQWKHWZRRIIHU
strategies within that period. In absolute terms, the total budget impact from 
LWVLQFRUSRUDWLRQLQ686LQ¿YH\HDUVZRXOGEH%5/86'DQG
%5/86'PLOOLRQUHVSHFWLYHO\7KHFRVWVIURPWKH3(7&7
SURFHGXUHZHUH WKHPRVW LQÀXHQWLDOSDUDPHWHU LQ WKHUHVXOWV ,Q WKHPRVW
optimistic scenario, the additional budget impact would be reduced to 
%5/86'DQG%5/86'PLOOLRQFRQVLGHULQJ3(7&7
for negative CT and PET-CT for all, respectively.
CONCLUSIONS: The incorporation of PET in the clinical staging of 
QRQVPDOOFHOOOXQJFDQFHUVHHPVWREH¿QDQFLDOO\IHDVLEOHFRQVLGHULQJWKH
KLJKEXGJHWRIWKH%UD]LOLDQ0LQLVWU\RI+HDOWK7KHSRWHQWLDOUHGXFWLRQLQ
the number of unnecessary surgeries may cause the available resources to 
EHPRUHHI¿FLHQWO\DOORFDWHG
DESCRIPTORS: Positron-Emission Tomography, economics. 
Carcinoma, Non-Small-Cell Lung, therapy. Health Care Costs. 
%XGJHWV8QL¿HG+HDOWK6\VWHP
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Economic evaluation of diagnostic and therapeutic 
interventions is gaining importance to support deci-
sions concerning the incorporation and dissemination 
of new health care technologies.22 Those analyses, 
however, do not provide all necessary information for 
decision-making, as they do not assess the feasibility 
for the introduction of the best alternative considering 
available budgets.11 The further conduction of budget 
impact analyses to evaluate short and medium-term 
¿QDQFLDO FRQVHTXHQFHV UHJDUGLQJ WKH LQFRUSRUDWLRQ
changed use, or withdrawal of a technology from the 
set of available interventions in the health care system 
LVUHTXLUHG2,8
%UD]LO UHSRUWV D KLJK QXPEHU RI OXQJ FDQFHU FDVHV
QHZFDVHVDUHHVWLPDWHGIRUa Non-small cell 
OXQJFDUFLQRPDV16&/&DFFRXQWIRU
of cases, which can be potentially cured with surgical 
resection in the localized disease.5,b Often, the diagnosis 
is achieved in advanced stages. Thus, due to the disease 
spread to mediastinal lymph nodes or distant metas-
WDVHVDWWKHWLPHRIGLDJQRVLVRQO\RISDWLHQWV
are considered operable.c
Evaluating the disease extension at the diagnosis is 
HVVHQWLDOIRUGH¿QLQJWKHUDSLHV7KDWDYRLGVLPSURSHU
SURFHGXUHVZKLFKFDQLQÀXHQFHSDWLHQWV¶VXUYLYDODQG
TXDOLW\RIOLIH7KHFOLQLFDOVWDJLQJLVPDLQO\FRQGXFWHG
by means of computed tomography of the thorax and 
upper abdomen (CT of thorax), according to the clin-
ical guidelines for the diagnosis and treatment of lung 
FDQFHUDVGLVFORVHGE\WKH%UD]LOLDQ0LQLVWU\RI+HDOWK
0+LQd That exam is mainly based in morpho-
logical changes.
Positron emission tomography (PET) which is either 
combined to computed tomography (PET-CT) or not, is 
based on metabolic activity, rather than only on anatom-
ical aspects. Both are more accurate than conventional 
LPDJLQJWHFKQLTXHVLQWKHHYDOXDWLRQRIPHGLDVWLQDODQG
in distant areas involvement.5 Its inclusion in the tradi-
tional diagnostic strategies may result in better manage-
ment of cases, with reduced numbers of unnecessary 
surgeries and decreased morbidity and mortality. 
Another advantage would be staging the lung disease 
and distant metastases with a single exam.14
INTRODUCTION
PET is starting to be disseminated in Brazil, and it was 
LQFOXGHGLQWKH%UD]LOLDQ8QL¿HG+HDOWK6\VWHP686
payrolls for procedures in April 2014.e The economic 
evaluation for the use of PET-CT in the staging of 
16&/& FRQGXFWHG IRU WKH 0+ LQ  IRXQG WKDW
PET-CT is more cost-effective when compared to 
the currently offered management strategy, which is 
CT-based.b7KHUHVXOWVFRQ¿UPLQWHUQDWLRQDO¿QGLQJV4 
ZKLFKVKRZEHQH¿WVLQLWVLQFOXVLRQIRUWKHVWDJLQJRI
16&/&SDWLHQWVPDLQO\ IRUSUHYHQWLQJXQQHFHVVDU\
surgeries, that pay off for the additional costs for using 
of the new technology.
7KH VWXG\ IURP  GLG QRW HYDOXDWH WKH ¿QDQ-
cial impacts from offering the procedure in Brazils 
public health care service network. Budget impact 
analyses are scarce in Brazil, especially concerning 
diagnostic imaging. In a health care system which 
is set to offer universal and comprehensive care, the 
concern with using resources is shown to be impor-
tant considering the dichotomic relationship among 
budget availability, extension of care, and continuous 
advancements in technology.
This study aimed to estimate the budget impact of the 
inclusion of PET-CT in the mediastinal and distant 
staging of non-small cell lung cancer.
METHODS
7KH EXGJHW LPSDFW HVWLPDWLRQ KDV DGRSWHG 686¶V
SHUVSHFWLYHDVD¿QDQFLQJDJHQWRIKHDOWKFDUHVHUYLFHV
as indicated by the Brazilian guideline.f
7KHFKRVHQKRUL]RQZDVD¿YH\HDURQHWR
considering the possible morosity in the reallocation of 
government budgets and restrictions in the availability 
and access to PET-CT.
The projected use of PET-CT was conducted under the 
epidemiological method. Eligible patients correspond to 
all newly-diagnosed cases. Thus, estimates for numbers 
of lung cancer cases for 2006 to 2014 were used, as 
disclosed by the Brazilian National Cancer Institute 
,1&$7DEOHZLWKRIWRWDOFDVHVDVVLJQHG
WR16&/&KLVWRORJLFDOW\SH5 The number of new cases 
a Ministério da Saúde. Instituto Nacional de Câncer. Estimativa 2014: incidência de câncer no Brasil. Rio de Janeiro (RJ); 2014. 
b Caetano R, Biz AN, Bastos CRG, Garay OU, Schluckebier L. Avaliação econômica: análise de custo-efetividade do uso da 18FDG-PET/TC 
no estadiamento do câncer pulmonar de células não pequenas: relatório preliminar de pesquisa. Rio de Janeiro (RJ): Instituto de Medicina 
Social da UERJ; 2013.
c National Collaborating Centre for Cancer. Lung cancer. The diagnosis and treatment of lung cancer. London: NICE; 2011 [cited 2012 Oct 10] 
(Nice Clinical Guidelines; 121). Available from: http://www.ncbi.nlm.nih.gov/books/NBK99021/ 
d Ministério da Saúde. Portaria nº 600, de 26 de junho de 2012. Aprova as diretrizes diagnósticas e terapêuticas do câncer de pulmão. Diário 
Oficial União. 28 Jun 2012;Seção1:210. 
e Ministério da Saúde. Portaria nº 7, de 22 de abril de 2014. Torna pública a decisão de incorporar o PET-CT no estadiamento clínico do câncer 
de pulmão de células não-pequenas potencialmente ressecável no Sistema Único de Saúde - SUS. Diário Oficial União. 23 Abr 2014;Seção1:78.
f Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Diretrizes metodológicas: análise de impacto orçamentário: 
manual para o Sistema de Saúde do Brasil. Brasília (DF); 2012. 
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ZHUHHVWLPDWHGE\DGPLWWLQJDFRYHUDJHIRUWKH
686VXSSRUWHGSDWLHQWSRSXODWLRQg
7KUHHDQDO\VLVVFHQDULRVZHUHGH¿QHGUHIHUHQFHVWUDWH-
gies of management that are widely used, based on CT 
of thorax for all patients); alternative 1 (use of PET-CT 
restricted to patients with previous negative CT results, 
allowing for coverage of situations with more limited 
access to PET-CT); alternative 2 (use of CT and PET-CT 
for all cases, with further clinical management being 
GH¿QHGE\ WKHFRPELQHGUHVXOWVRI WKH WZRH[DPV±
only patients with both negative images would directly 
proceed to pulmonary resection). This last strategy 
yielded a higher reduction in the number of unnecessary 
surgeries in the cost-effective study used as basis,b with 
small differences in the incremental cost-effectiveness 
ratio between the two usage methods for PET-CT in the 
conducted sensitivity analyses.
Only direct costs of procedures involved in the staging 
and therapies of patients were considered (Table 2). 
$V WKH3(7&7SURFHGXUHZDVQRW LQFOXGHG LQ686
payrolls when the analyses were conducted, we used 
values as estimated by micro-costing. The values 
ZHUH FDOFXODWHG DJDLQ WR KDYH D  UHGXFWLRQ LQ
WKH)ÀXRURGHR[\'JOXFRVHFRVWV18)'*h to 
consider the recent increase in the number of private 
input producers which took place when the Federal 
*RYHUQPHQWORVWLWVPRQRSRO\IRUUDGLRSKDUPDFHXWL-
FDOVLQ)RUDOOSURFHGXUHV¿JXULQJLQ686SD\UROO
FKDUWV YDOXHV UHJDUGLQJ1RYHPEHUZHUHXVHG
ZKLFK ZHUH OLVWHG LQ 686 0DQDJHPHQW 6\VWHP IRU
the Chart of Procedures, Medications, and Orthoses, 
3URVWKHWLFVDQG6SHFLDO0DWHULDOVi
For the budget impact estimates, the same decision trees 
and parameters that were used in the cost-effectiveness 
VWXG\FRQGXFWHGIRU0+LQZHUHXVHGDJDLQKHUHb 
The new cases projected for each year and the costs of 
procedures fed the trees related to each analysis scenario, 
ZKLFKJHQHUDWHGHVWLPDWHVIRUTXDQWLWLHVRIFRQGXFWHG
procedures and total costs associated to that target popu-
lation. The yearly budget impacts and the budgets for the 
period between 2014 and 2018 were calculated for each 
scenario. No discounts rates or values regarding adjust 
IRULQÀDWLRQZHUHLQWURGXFHGLQFRPSOLDQFHWRLQWHUQD-
tional and nationalf guidelines for this type of study.
The incremental budget impact for each examined year 
was calculated by means of the difference between 
the total budget impacts for the alternative and refer-
ence scenarios. The incremental difference among the 
alternative strategies was evaluated, which enabled the 
analysis of a wider and more restricted offer of technology.
Univariate and extreme scenarios sensitivity analyses 
were conducted to consider the uncertainties related to 
parameter values and premises used.15 The evaluated 
SDUDPHWHUVLQWKH¿UVWRQHVZHUHWKHDQQXDOYDULDWLRQ
rate of lung cancer cases; costs of PET-CT procedure; 
prevalence of mediastinal and distant lesions; prob-
DELOLW\RI FRQGXFWLQJ FRQ¿UPDWRU\PHGLDVWLQRVFRS\
and CT and PET-CT sensitivity. The same ranges of 
values that were obtained in the literature and used in 
WKHVWXG\IRUWKH0+ZHUHXVHGKHUHb
7KHSDUDPHWHUVZHUH VLPXOWDQHRXVO\PRGL¿HG LQ WKH
extreme scenarios sensitivity analysis. The best-case 
scenario corresponded to minimizing the budget impact 
from PET incorporation for any alternative scenario 
DGRSWHG7KHPLQLPXPYDOXHVLQWKHUDQJHWKDW¿JXUHV
LQ7DEOHIRUWKHIROORZLQJSDUDPHWHUZHUHHPSOR\HG
costs of PET-CT, annual variation rate for the number 
RIQHZFDVHV DQG&7VHQVLWLYLW\6LPXOWDQHRXVO\ WKH
following were employed considering their maximum 
YDOXHVELRSV\VHQVLWLYLW\VKDUHRISDWLHQWVKDYLQJXQGHU-
gone mediastinoscopy procedure; and prevalence of 
PHWDVWDVHVLQPHGLDVWLQDOO\PSKQRGHV1DQGGLVWDQW
metastases (M1). The worst-case scenario corre-
sponded to the same parameters varying in the opposite 
direction to the one mentioned above.
0RUHRYHU WKH LQÀXHQFH IURP WKH UDWH E\ ZKLFK WKH
WHFKQRORJ\ LV GLVVHPLQDWHG DW 686 ZDV DQDO\]HG ,W
LVSRVVLEOH WKDW HYHQZLWK LWEHLQJ LQFOXGHG LQ686
payrolls, delays may take place until it is fully offered, 
GXHWRWKHFXUUHQWJHRJUDSKLFDODYDLODELOLW\RIHTXLS-
PHQWDQGTXDOL¿HGVWDIIIRULWVRSHUDWLRQ6L[W\SHUFHQW
of patients were considered eligible for using PET-CT 
LQZLWKLQFUHDVHVZLWKHDFK\HDUXQWLOIXOO
access was achieved in 2018.
Written authorization was obtained from the Project 
&13T  FRRUGLQDWRU FRQFHUQLQJ WKH
usage of data and model of the cost-effectiveness study.
RESULTS
The current diagnostic and therapeutic management 
PRGHO IRU 16&/& SDWLHQWV LQ %UD]LOLDQ KHDOWK FDUH
services, which is focused on CT use, would result in 
 %5/  86' PLOOLRQ LQ H[SHQGLWXUHVj in 
¿YH\HDUVIRU686.
g Agência Nacional de Saúde Suplementar. Caderno de informação da Saúde Suplementar: beneficiários, operadoras e planos. Rio de Janeiro (RJ); 2013. 
h Ministério da Ciência, Tecnologia e Inovação. Comissão Nacional de Energia Nuclear (CNEN). Relatório de Gestão do Exercício de 2011. 
Rio de Janeiro (RJ); 2012. 
i Ministério da Saúde. Departamento de Informática do SUS (DATASUS). Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos 
e OPM do SUS (SIGTAP). Brasília (DF); 2013 [cited 2013 Nov 25]. Available from: http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp
j The conversion of all monetary amounts to the American dollar that is presented in the text, in the tables, and figure, was conducted based 
on the PPP conversion factor for Brazil, regarding the year of 2013, as disclosed by the World Bank. PPP conversion factor, GDP (LCU per 
international $). Washington (DC): World Bank; 2015 [cited 2015 May 2]. Available from: http://data.worldbank.org/indicator/PA.NUS.PPP
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Table 2. Cost parameters (in PPP-adjusted US$, as per 2013 rates)*, accuracy, and epidemiological data that were used in the 
budget impact analysis and data source.
Parameter Value Range References
Costs*
CT of thorax (US$) 84.73 – Sigtap/DataSUSi
Whole body PET-CT (US$) 1,662.58 1,017.31;1,818.13 Caetano3 (2014) + Premises
Mediastinoscopy (US$) 860.37 – Sigtap/DataSUSi
Biopsy (US$) 598.68 – Sigtap/DataSUSi
Surgery (US$) 2,687.32 – Sigtap/DataSUSi
Chemotherapy + Radiotherapy (US$) 2,416.15 – Sigtap/DataSUSi
Palliative care (US$) 683.23 – Sigtap/DataSUSi
Deaths from mediastinoscopy (US$) 1,687.77 – Sigtap/DataSUSi
Accuracy
CT of thorax sensitivity for 
mediastinal lymph nodes (%)
51 47;62 Dwamena7 (1999); Silvestri18 (2007)
Biopsy sensitivity for distant 
metastases (%)
100 80;100 Gambhir9 (1996); Sloka19 (2004)
Epidemiological parameters 
Variation rate of number of cases (%) 0.0754 -1.1983;0.4054 Estimates from INCA in 2005, 2007, 2009, 
2011, and 2014
Prevalence of distant metastases (%) 20 12;25 NICE 2011c
Prevalence of metastases in 
mediastinal lymph nodes (%)
30 15;40 Dietlein6 (2000); NICE 2011c
Probability for conduction of 
mediastinoscopy (%)
50 0;100 Alzahouri1 (2005) refers to specialists
CT: Computed tomography; INCA: Brazilian National Cancer Institute; PET-CT: Positron emission tomography along with 
computed tomography
* World Bank’s PPP conversion rate for 2013 (PPP-adjusted USD): 1 USD = 1.61 BRL.
Table 1. Cases of lung cancer and NSCLC, from 2006 to 2014, and the projected number of new NSCLC cases, from 2006 to 
2014, and the ones handled by the Brazilian Unified Health System, from 2014 to 2018.
Year New lung cancer cases New NSCLC cases New NSCLC cases handled by SUS
2006 27,170 23,095 –
2007 27,170 23,095 –
2008 27,270 23,180 –
2009 27,270 23,180 –
2010 27,630 23,486 –
2011 27,630 23,486 –
2012 27,320 23,222 –
2013 27,320 23,222 –
2014a 27,330 23,231 17,423
2015b – 23,248 17,436
2016b – 23,266 17,449
2017b – 23,283 17,462
2018b – 23,301 17,475
Source: Estimates from the data regarding number of cancer cases, as disclosed by the Brazilian National Cancer Institute in 
2005, 2007, 2009, 2011, and 2014.
NSCLC: Non-small cell lung cancer; SUS: Sistema Único de Saúde (Brazilian Unified Health System)
a The preliminary data from the following source were repeated: Ministério da Saúde. Instituto Nacional de Câncer. 
Estimativa 2014: incidência de câncer no Brasil. Rio de Janeiro (RJ); 2014.
b Estimated from the variation regarding years 2006 to 2014.
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7KHLQWURGXFWLRQRI3(7&7LQ16&/&VWDJLQJZRXOG
LPSO\ DQ LQFUHDVH LQ WRWDO H[SHQGLWXUHV IRU 686
7DEOHGXHWRLWVFRPSOHPHQWDU\QRQUHSODFHDEOH
nature, regardless of the strategy for its use. Its 
restricted use in patients with negative CT of thorax 
results would determine a total impact of 555.5 BRL 
 86' PLOOLRQ RYHU WKH SHULRG  DV
compared to the current management). Its use for 
all patients would cause an impact of 600.1 BRL 
86'PLOOLRQ
7KH¿QDQFLDOLPSDFWIURPWKHPRUHUHVWULFWHG3(7&7
offer would imply an additional allocation of 158 BRL 
86'PLOOLRQLQ¿YH\HDUV7DEOH([WHQGLQJ
the offer to all potential candidates would involve 
%5/86'PLOOLRQLQDGGLWLRQDOUHVRXUFHV
ZLWK%5/86'PLOOLRQEHLQJWKHGLIIHUHQFH
between the strategies at the end of the period.
The cost of PET-CT procedure was the parameter with 
the biggest impact in the univariate sensitivity analyses 
(Figure) using the values from the range in Table 2. The 
UHGXFWLRQLQWKHFRVWRIWKHSURFHGXUHWR%5/
86'ZRXOGFDXVHDWRWDO¿YH\HDUEXGJHW
LPSDFWUHGXFWLRQRI%5/86'PLOOLRQLQ
WKHUHVWULFWHGRIIHUDQG%5/86'
PLOOLRQLQWKHPRVWLQFOXVLYHXVH7KHGLIIHU-
ence from the two strategies would drop to 21.9 BRL 
86'PLOOLRQ$QLQFUHDVHLQWKHFRVWRIWKHSURFH-
GXUHWR%5/86'ZRXOGUHVXOWLQ
UHODWLYHO\VPDOOHULQFUHDVHVLQWKHWRWDOEXGJHWLPSDFW
%5/86'PLOOLRQLQWKHUHVWULFWHG
RIIHUDQG%5/86'PLOOLRQLQWKH
inclusive offer.
The variation in the share of patients submitted to medi-
DVWLQRVFRS\WRFRQ¿UPLPDJLQJH[DPUHVXOWVEHWZHHQ
DQGZDVVKRZQWREHLPSRUWDQWJLYHQWKHLU
FRVWV WR 686 1RQSHUIRUPDQFH RI PHGLDVWLQRVFRS\
corresponded to a reduction in the total budget impact of 
%5/86'PLOOLRQLQWKH³3(7&7IRU&7´
VFHQDULRDQG%5/86'PLOOLRQLQWKHXVH
of PET for all. Its conduction in all patients, on the 
other hand, would lead to increases in both scenarios 
of the same amounts mentioned above.
The use of the lower value of the range of the growth 
RIVWDJLQJHOLJLEOH16&/&FDVHVSURGXFHGGHFUHDVHV
in the budget impact regardless of the analyzed 
VFHQDULR IURP  %5/  86' PLOOLRQ LQ WKH
³3(7&7IRU&7´VFHQDULRDQG%5/86'
million, with the offer of PET-CT for all. Using the 
upper limit of that parameter resulted in increases of 
%5/86'PLOOLRQDQG%5/86'
million, respectively.
The extreme scenarios sensitivity analyses (Table 4) 
VKRZHGVLJQL¿FDQWUHGXFWLRQLQWRWDOEXGJHWLPSDFWLQ
WKH³EHVWFDVHVFHQDULR´%5/86'PLOOLRQ
LQWKHLQFOXVLYHXVHRI3(7&7DQG%5/
86'LQWKHUHVWULFWHGRIIHU7KHLQFRU-
poration would result in increased budget impacts of 
%5/86'PLOOLRQLQWKH³3(7&7IRUDOO´
VWUDWHJ\DQG%5/86'PLOOLRQLQ
WKHUHVWULFWHGXVHLQWKH³ZRUVWFDVHVFHQDULR´
The total reduction in the budget impact would be of 
%5/86'PLOOLRQLQWKHVFHQDULR
with the restricted offer of the technology, and 44 BRL 
 86' PLOOLRQ ZLWK DYDLODELOLW\ WR DOO 
FRQVLGHULQJDSURJUHVVLYHGLVVHPLQDWLRQ±IURP
WRLQ¿YH\HDUV±RI3(7&7DW686
DISCUSSION
7KHLQFRUSRUDWLRQRI3(7&7LQWKHVWDJLQJRI16&/&D
highly relevant neoplasia in Brazils nosological scenario, 
ZRXOGLPSO\WRWDOH[SHQGLWXUHVRI%5/86'
PLOOLRQWR686LQFDVHLWVXVHLVUHVWULFWHGWRSDWLHQWVZLWK
Table 3. Total and incremental budget impact per year and for 2014 to 2018, regarding the studied analysis scenarios (in 
PPP-adjusted USD from 2013)a.
Period
Total budget impacta Incremental budget impacta
CT PET-CT for CT-b PET-CT for allc
PET-CT for CT-b 
regarding CT
PET-CT for allc 
regarding CT
PET-CT for allc regarding 
PET-CT for CT-b
2014 49,297,708.43 68,902,114.70 74,438,876.78 19,604,406.27 25,141,168.35 5,536,762.07
2015 49,334,855.45 68,954,034.11 74,494,968.27 19,619,178.66 25,160,112.83 5,540,934.16
2016 49,372,030.45 69,005,992.65 74,551,102.03 19,633,962.19 25,179,071.58 5,545,109.39
2017 49,409,233.47 69,057,990.34 74,607,278.09 19,648,756.86 25,198,044.61 5,549,287.76
2018 49,446,464.53 69,110,027.20 74,663,496.48 19,663,562.67 25,217,031.96 5,553,469.28
2014-2018 246,860,292.33 345,030,158.99 372,755,721.65 98,169,866.66 125,895,429.32 27,725,562.65
CT: Computed tomography; PET-CT: Positron emission tomography along with computed tomography
a World Bank’s PPP conversion rate for 2013 (PPP-adjusted USD for 2013): 1 USD = 1.61 BRL.
b PET-CT for CT-: conduction of PET-CT only for patients with negative CT results.
c PET-CT for all: conduction of PET-CT for all patients, considering both the results from PET and CT for resuming the 
clinical, therapeutic management.
6 Budget impact from PET-CT on SUS Biz AN & Caetano R
(a) CTb
(b) PET-CT for negative CT
Proportion of mediastinoscopies conducted
CT sensitivity for mediastinal lymph nodes
Prevalence of mediastinal metastases
Variation rate of number of cases
235
Maximum Minimum
240 250245 255 260
US$ Million
US$ Million
US$ Million
Maximum Minimum
Maximum Minimum
Proportion of mediastinoscopies conducted
Biopsy sensitivity
CT sensitivity for mediastinal lymph nodes
Prevalence of mediastinal metastases
Prevalence of distant metastases
Variation rate of number of cases
PET-CT Costs
Proportion of mediastinoscopies conducted
Biopsy sensitivity
CT sensitivity for mediastinal lymph nodes
Prevalence of mediastinal metastases
Prevalence of distant metastases
Variation rate of number of cases
PET-CT Costs
300 313 326 339 352 365
(c) PET-CT considering results from PET and CT
315 330 345 360 375 390
CT: Computed tomography; PET-CT: Positron emission tomography along with computed tomography; PET-CT for CT-: 
conduction of PET-CT only for patients with negative CT results; PET-CT for all: conduction of PET-CT for all patients, 
considering both the results from PET and CT for resuming the clinical, therapeutic management
a World Bank’s PPP conversion rate for 2013 (PPP-adjusted USD for 2013): 1 USD = 1.61 BRL.
b The usual staging with CT has not included variable prevalence of distant metastases, biopsy sensitivity, and cost of PET-CT. 
This type of staging strategy does not include the new technology, nor does it assess distant metastases, only the local ones; 
hence its results are not altered with changes in the first one, nor do they need to be confirmed through biopsy.
Figure. Result from the total budget impact univariate sensitivity analysis (in PPP-adjusted dollars from 2013).a Evaluated 
scenarios, Brazil, 2014 to 2018.
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previous negative results in computed tomography of 
WKRUD[DQG%5/86'PLOOLRQLQWKHVLWXD-
tion in which it is offered to all new cases that are diagnosed 
in the period. These values represent additional costs to the 
current expenditures with computed tomography-based 
VWDJLQJRIDURXQG%5/86'WR%5/
86'PLOOLRQLQ¿YH\HDUVGHSHQGLQJRQLWVPRUH
restricted or inclusive use. In absolute or incremental terms, 
the estimated values reinforce the importance of properly 
planning and managing of budgets and governmental 
actions, including health care, in a way to optimize the 
XVHRIDYDLODEOHUHVRXUFHVZKLFKDUHVFDUFHLQRXU¿HOG
7KH1DWLRQDO3ROLF\RQ+HDOWK7HFKQRORJLHV0DQDJHPHQWk 
and Law 12,401l have recognized the role of complemen-
tary economic evaluation. The conduction of budget impact 
studies to support decisions regarding the incorporation 
RIQHZWHFKQRORJLHVDW686LVH[SOLFLWO\UHFRPPHQGHG
2QHRI686¶VFKDOOHQJHVOLHVLQLWVFRPSOLDQFHWRWKH
principle that health services should follow the principle 
of universality. Offering PET-CT to all candidates may 
QRWEHIHDVLEOHGXHWR¿QDQFLDOLQIUDVWUXFWXUDORUKXPDQ
resources limitations, among others. That acknowledg-
ment, plus the fact that the literature and the study to the 
0LQLVWU\RI+HDOWKSRLQWWRZDUGVKLJKHUKHDOWKEHQH¿WV
for the group with previous negative CT exams6,b led 
to the simulation of the restricted offer for the exam. 
+RZHYHUH[WHQGLQJWKHRIIHUWRDOOSRWHQWLDOFDQGLGDWHV
would result in an increased total budget impact of only 
%5/86'PLOOLRQDWWKHHQGRIWKHSHULRG
The extent of the impacts which are associated with the 
LQFRUSRUDWLRQRI3(7&7ZRXOGKDYHVLJQL¿FDQW¿QDQ-
cial implications, especially if the number of eligible 
SDWLHQWVZHUHZHLJKWHGLQ7KDWLVVREHFDXVHLQ
the number of new lung cancer cases corresponded to 
RQO\RIWKH%UD]LOLDQSRSXODWLRQ
7KH H[SHQGLWXUHV RI WKH 0LQLVWU\ RI +HDOWK ZKLFK
¿JXUHLQWKH$QQXDO%XGJHW$FWIRUm were looked 
after for better understanding of the meaning of the 
resources volumes which were estimated with the incor-
poration of PET-CT. The estimated amount needed to 
PDLQWDLQ 686¶V FXUUHQW PDQDJHPHQW RI WKH GLVHDVH
FRUUHVSRQGVWRRIWKH%5/
86'WKDWZHUHSUHGLFWHGIRU
In the alternative scenarios, the total budget impact 
HVWLPDWHG ZRXOG FRUUHVSRQG WR  RI WKH 0+
EXGJHWUHVWULFWHGRIIHURUWRLQFOXVLYHRIIHU
Another way to examine how substantial the estimated 
impacts are would be to compare them to the sums which 
DUHVSHQWE\686ZLWKFDUHRIOXQJFDQFHUSDWLHQWVHJ
related to diagnostics and treatment in their various 
PRGDOLWLHV+RZHYHUQRFRQVROLGDWHGLQIRUPDWLRQZDV
IRXQGLQWKHOLWHUDWXUHQRUZDVLWLQRI¿FLDOGRFXPHQWV
about expenditures made for that condition. The expen-
GLWXUHVIURPWKH0LQLVWU\RI+HDOWKWKDWDUHUHODWHGWR&7
RIWKRUD[H[DPVFRQGXFWHGDQGDSSURYHGE\686FDQEH
obtained from the Sistema de Informações Ambulatoriais 
6\VWHPRI$PEXODWRULDO,QIRUPDWLRQn But this infor-
mation correspond to the use of the procedure in several 
clinical indications (neoplastic or non-neoplastic), and 
not only for lung cancer, which renders any comparison 
impossible. The expenditures with inpatient care from 
686UHODWHGWROXQJFDQFHUZKLFKZHUHREWDLQHGIURP
the Sistema de Informações Hospitalares 6\VWHPRI
+RVSLWDO,QIRUPDWLRQDGGHGXSWR%5/
86'IURP-DQXDU\WR1RYHPEHUo 
7KDWPDNHVXSIRURIWKH%5/86'
million of the budget impact that was estimated in the 
reference scenario for 2014, but it does not include the 
remaining diagnostic and therapeutic components which 
are involved with handling the condition.
The dissemination of PET-CT into the clinical prac-
tice took place in a context in which concern with 
expenditures and impacts for health care systems was 
building up. Thus, the technology was the subject of 
several cost-effectiveness studies in several countries. 
Budget impact evaluations for its implementation are 
OHVV IUHTXHQW LQ WKH OLWHUDWXUH DQG WKDW LV PD\EH VR
because they are conducted internally in the govern-
mental environment which is involved with offering the 
technology. Nonetheless, directly comparing the results 
of those budget impact analyses with the ones herein is 
inappropriate. That is so because the management and 
organization of health care systems, structures of their 
models, epidemiological data, and especially the under-
lying cost structures greatly differ among studies.17
Comparing budget impact estimates that are conducted 
LQRXUUHDOLW\ZRXOGEHLGHDO(YHQWKRXJKWKH0+KDV
internally simulated the budget impact from PET at 
686p its estimation methods and likelihood of bearing 
k Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Política de Gestão de Tecnologias em saúde. Brasília (DF); 2011.
l Brasil. Lei nº 12.401, de 28 de abril de 2011. Altera a Lei nº 8.080, de 19 de setembro de 1990, para dispor sobre a assistência terapêutica e 
incorporação de tecnologias em saúde no âmbito do SUS. Diário Oficial União. 29 Abr 2011:Seção1:1-2.
m Senado Federal. Portal do Orçamento. Lei Orçamentária Anual 2014: Volume IV –Detalhamento das Ações – Órgão do Poder Executivo – 
Presidência da República e Ministérios (exceto MEC). 36000. Brasília (DF); 2014 [cited 2014 Jan 13]. Available from: http://www12.senado.gov.
br/orcamento/loa?ano=2014&categoria=3.1.7&fase=elaboracao 
n Ministério da Saúde. Departamento de Informática do SUS (DATASUS). Sistema de Informações Ambulatoriais do SUS (SIA/SUS). Brasília 
(DF); 2014. Available from: http://www2.datasus.gov.br/DATASUS/index.php?area=0202
o Ministério da Saúde. Departamento de Informática do SUS (DATASUS). Sistema de Informações Hospitalares do SUS (SIH/SUS). Brasília 
(DF); 2014 [cited 2014 Jan 15]. Available from: http://www2.datasus.gov.br/DATASUS/index.php?area=0202
p Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. PET-TC no estadiamento de câncer pulmonar de células 
não-pequenas. Relatório de Recomendação da Comissão Nacional de Incorporação de Tecnologias no SUS – CONITEC-107. Brasília (DF); 
2014. Available from: http://portalsaude.saude.gov.br/images/pdf/2014/abril/23/Relatorio-PET-EstadiamentoCancerPulmonar-FINAL.pdf 
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q Tribunal de Contas da União. Política Nacional de Atenção Oncológica; Relator Ministro José Jorge. Brasília (DF); 2011. 
important methodological biases hinders comparisons 
with the results from this study. Besides that, according 
to the budget impact guidelines, estimates should not 
be restricted to comparing amounts and prices of tech-
QRORJLHVSHUVHEXWWRWKH¿QDQFLDOUHVXOWIURPWKHVHW
RI FOLQLFDO FRQVHTXHQFHV DQG GLDJQRVWLF WKHUDSHXWLF
procedures that relate to examined technologies, as 
this study aimed at.
$OWKRXJKHPSOR\LQJ3(7GRHVQRWVKRZDVLJQL¿FDQW
increase in the survival of patients,4 its use allows for 
EHWWHU¿QDQFLDOPDWHULDODQGKXPDQUHVRXUFHGLVWUL-
EXWLRQLQWKHV\VWHPDVLWPRUHDFFXUDWHO\LGHQWL¿HVWKH
extension of disease and allows planning the therapeutic 
VWUDWHJ\WKDWLVWKHPRVWDGHTXDWHWRHDFKFDVH6XFK
smoother method would prevent unnecessary surgical 
procedures, which is more relevant when there are 
famous problems with access to health care services in 
WKHFRXQWU\HVSHFLDOO\UHJDUGLQJRQFRORJ\DQGVLJQL¿-
cant regional discrepancies in its offer.T
Budget impact studies are scarce, and only more 
recently they have gained guidelines on good prac-
tices more established. This study followed the main 
available guidelines on budget impact analyses from 
7DVN )RUFH RQ *RRG 5HVHDUFK 3UDFWLFHV IURP WKH
,QWHUQDWLRQDO 6RFLHW\ IRU 3KDUPDFRHFRQRPLFV DQG
Outcomes Research and the ones from the Ministry 
Table 4. Total and incremental budget impact analyses of staging strategies per projected year (in PPP-adjusted USD from 
2013)a. Brazil, 2014 to 2018.
Period
Total budget impacta Incremental budget impacta
CT PET for CT-b PET-CT for allc
PET for CT-b 
regarding CT
PET-CT for allc 
regarding CT
PET-CT for allc 
regarding PET for CT-b
Base case
2014 49,297,708.43 68,902,114.70 74,438,876.78 19,604,406.27 25,141,168.35 5,536,762.07
2015 49,334,855.45 68,954,034.11 74,494,968.27 19,619,178.66 25,160,112.83 5,540,934.16
2016 49,372,030.45 69,005,992.65 74,551,102.03 19,633,962.19 25,179,071.58 5,545,109.39
2017 49,409,233.47 69,057,990.34 74,607,278.09 19,648,756.86 25,198,044.61 5,549,287.76
2018 49,446,464.53 69,110,027.20 74,663,496.48 19,663,562.67 25,217,031.96 5,553,469.28
2014-2018 246,860,292.33 345,030,158.99 372,755,721.65 98,169,866.66 125,895,429.32 27,725,562.65
Best-case scenariod
2014 51,669,368.28 62,721,624.22 64,875,377.64 11,052,256.14 13,206,009.32 2,153,753.42
2015 51,050,206.32 61,970,021.74 64,097,965.84 10,919,815.26 13,047,759.63 2,127,944.72
2016 50,438,463.86 61,227,425.47 63,329,870.19 10,788,961.44 12,891,406.21 2,102,445.34
2017 49,834,052.01 60,493,727.95 62,570,978.88 10,659,675.66 12,736,926.71 2,077,250.93
2018 49,236,882.92 59,768,821.74 61,821,181.37 10,531,939.13 12,584,298.14 2,052,359.01
2014-2018 252,228,973.39 306,181,621.01 316,695,374.12 53,952,647.63 64,466,400.74 10,513,753.11
Worst-case scenarioe
2014 47,295,407.04 71,202,595.65 77,144,317.39 23,907,188.32 29,848,910.56 5,941,721.74
2015 47,487,161.13 71,491,278.26 77,457,090.68 24,004,117.42 29,969,929.19 5,965,811.80
2016 47,679,692.66 71,781,132.30 77,771,131.68 24,101,439.50 30,091,439.13 5,990,000.00
2017 47,873,004.79 72,072,160.87 78,086,446.58 24,199,156.16 30,213,441.61 6,014,285.71
2018 48,067,100.68 72,364,369.57 78,403,039.75 24,297,269.01 30,335,939.13 6,038,669.57
2014-2018 238,402,366.32 358,911,536.71 388,862,025.90 120,509,170.40 150,459,659.58 29,950,489.18
CT: Computed tomography; PET-CT: Positron emission tomography along with computed tomography
a World Bank’s PPP conversion rate for 2013 (PPP-adjusted USD for 2013): 1 USD = 1.61 BRL.
b PET-CT for CT-: conduction of PET-CT only for patients with negative CT results.
c PET-CT for all: conduction of PET-CT for all patients, considering both the results from PET and CT for resuming the 
clinical, therapeutic management.
d Best-case scenario: variation for the lower limit of the parameter interval: cost of PET-CT, annual variation in number of 
cases, and CT sensitivity; and for maximum values of parameters: biopsy sensitivity, share of patients who were submitted to 
mediastinoscopy and prevalences of metastases in mediastinal lymph nodes (N2/3) and distant metastases (M1).
e Worst-case scenario: variation for the upper limit of the parameter interval: cost of PET-CT, annual variation in number of 
cases, and CT sensitivity; and for minimum values of parameters: biopsy sensitivity, share of patients who were submitted to 
mediastinoscopy and prevalences of N2/3 and M1.
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RI+HDOWKZKLFKZHUH UHFHQWO\SXEOLVKHGf5HTXLUHG
adaptations were made, as they mainly focus on thera-
peutic procedures.
'HVSLWH RXU XVLQJ D QLQH\HDU WLPH VHULHV  WR
2014) to estimate future lung cancer new cases, it was 
not possible to predict possible alterations arising from 
population changes or in the prevalence of some of its 
risk factors. Besides that, this study used parameter 
values from the cost-effectiveness study. Thus, the same 
limitations from before remain, as a gap in the national 
data regarding some epidemiological parameters, accu-
racy measurements for diagnostic technologies from 
international studies, and from the missing information 
about the share of patients who are submitted to medi-
astinoscopy within the country. The multiple sensitivity 
analyses conducted aimed at shedding some light on 
those uncertainties, and potentializing the knowledge 
UHJDUGLQJWKHH[WHQWRIWKHLPSDFWWKH\JHQHUDWHWR686
Trueman et al20 discuss the incompatibility between 
WKH HIIRUW WR PD[LPL]H HI¿FLHQF\ ZKLFK LV WKH FRUH
target of economists, and the limits for the current 
budgets, which is commonly the main need from 
managers. Budget impact analyses do not show the best 
way to distribute available resources in the economy, 
whose most proper evidence come from compre-
hensive economic evaluation studies, such as the 
cost-effectiveness ones. Furthermore, the decisions to 
incorporate technologies in health care systems must 
take into account other factors, such as the availability 
of human and budget resources, political factors, and 
DVSHFWVUHJDUGLQJHTXDODFFHVVWRKHDOWKFDUH
'DWDWKDWLVVLPLODUWRWKHRQHVLQWKLVVWXG\DORQJZLWK
the evidence the technology is cost-effective in Brazil, 
may allow decisions taken to be properly backed up. 
Thus, the incorporation of PET in the clinical staging 
RI SRWHQWLDOO\ UHVHFWDEOH 16&/& VHHPV WR EH ¿QDQ-
cially feasible considering the high total budget from 
%UD]LO¶V0LQLVWU\RI+HDOWKDQGWKHSRWHQWLDOUHGXFWLRQ
in the number of unnecessary surgeries better staged 
patients are submitted to. This may cause the available 
UHVRXUFHVWREHPRUHHI¿FLHQWO\GLVWULEXWHG
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